131 related articles for article (PubMed ID: 32657941)
41. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
43. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.
Partain N; Postlewait LM; Teshome M; Rosso K; Hall C; Song J; Meas S; DeSnyder SM; Lim B; Valero V; Woodward W; Ueno NT; Kuerer H; Lucci A
Ann Surg Oncol; 2021 Aug; 28(8):4265-4274. PubMed ID: 33403525
[TBL] [Abstract][Full Text] [Related]
44. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
45. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.
Libé R; Borget I; Ronchi CL; Zaggia B; Kroiss M; Kerkhofs T; Bertherat J; Volante M; Quinkler M; Chabre O; Bala M; Tabarin A; Beuschlein F; Vezzosi D; Deutschbein T; Borson-Chazot F; Hermsen I; Stell A; Fottner C; Leboulleux S; Hahner S; Mannelli M; Berruti A; Haak H; Terzolo M; Fassnacht M; Baudin E;
Ann Oncol; 2015 Oct; 26(10):2119-25. PubMed ID: 26392430
[TBL] [Abstract][Full Text] [Related]
47. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
48. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
49. Incorporation of biologic factors for the staging of de novo stage IV breast cancer.
He ZY; Lian CL; Wang J; Lei J; Hua L; Zhou J; Wu SG
NPJ Breast Cancer; 2020; 6():43. PubMed ID: 32964117
[TBL] [Abstract][Full Text] [Related]
50. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
51. Breast cancer in Bedouin-Arab patients in southern Israel: epidemiologic and biologic features in comparison with Jewish patients.
Lazarev I; Flaschner M; Geffen DB; Ariad S
Asian Pac J Cancer Prev; 2014; 15(18):7533-7. PubMed ID: 25292024
[TBL] [Abstract][Full Text] [Related]
52. Factors affecting survival in breast cancer patients following bone metastasis.
Yavas O; Hayran M; Ozisik Y
Tumori; 2007; 93(6):580-6. PubMed ID: 18338493
[TBL] [Abstract][Full Text] [Related]
53. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.
Weiss A; King TA; Hunt KK; Mittendorf EA
Surg Clin North Am; 2018 Aug; 98(4):687-702. PubMed ID: 30005768
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
55. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
Xiao Y; Li J; Wu Z; Zhang X; Ming J
Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
[TBL] [Abstract][Full Text] [Related]
56. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
57. Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis.
Zimmerman BS; Seidman D; Cascetta KP; Ru M; Moshier E; Tiersten A
Oncology; 2021; 99(5):280-291. PubMed ID: 33652435
[TBL] [Abstract][Full Text] [Related]
58. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
59. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.
Zeichner SB; Herna S; Mani A; Ambros T; Montero AJ; Mahtani RL; Ahn ER; Vogel CL
Breast Cancer Res Treat; 2015 Oct; 153(3):617-24. PubMed ID: 26358708
[TBL] [Abstract][Full Text] [Related]
60. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
